Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of sonrotoclax alone or with zanubrutinib in Waldenström macroglobulinemia
CTR20232718Phase 2Active
- Sponsor
- BeiGene
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sonrotoclax in Waldenström macroglobulinemia (WM), sponsored by BeiGene. Started Jan 2024; status: active.
02
Drugs
sonrotoclax
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on CTR20232718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232718.